Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40236 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1725586 (State or other jurisdiction of (I.R.S. ...

Table of Contents (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40236 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1725586 (State or other jurisdiction of (I.R.S. Employer incorporation or organization ...

A Novel Approach to Tackling Rare Progressive Muscle Disorders 1 Corporate Presentation May 2022 Disclaimer 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"). All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40236 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1725586 ( ...

A Novel Approach to Tackling Rare Progressive Muscle Disorders Corporate Presentation May 2022 1 Disclaimer 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"). All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for ...

Table of Contents (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40236 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1725586 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Id ...

Table of Contents 3415 Colorado Ave. Boulder, CO 80303 (Address of Principal Executive Offices) (720) 262-7002 (Registrant's telephone number) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40236 Edgewise Therapeu ...

| --- | |-------| | | | | | | CONFIDENTIAL Our vision is to improve the lives of patients and families suffering from rare muscle disorders NASDAQ: EWTX Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"). All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, results of oper ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40236 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1725 ...

Financial Performance - For the three months ended June 30, 2021, total operating expenses were $10.5 million, an increase of $6.5 million compared to $4.0 million for the same period in 2020[106]. - The net loss for the three months ended June 30, 2021, was $10.4 million, compared to a net loss of $4.0 million for the same period in 2020[106]. - The net loss for the six months ended June 30, 2021, was $17.2 million, compared to a net loss of $7.1 million in 2020, reflecting a $10.1 million increase[111]. - Cash used in operating activities was $15.8 million for the six months ended June 30, 2021, compared to $6.7 million in 2020, indicating a significant increase in cash outflow[117]. Expenses - Research and development expenses for the three months ended June 30, 2021, were $7.9 million, up from $3.6 million in 2020, primarily due to increased costs associated with the Phase 1 clinical trial of EDG-5506[107]. - General and administrative expenses rose to $2.6 million for the three months ended June 30, 2021, compared to $0.3 million in 2020, largely due to costs related to operating as a public company[108]. - Research and development expenses increased to $13.2 million for the six months ended June 30, 2021, up from $6.6 million in 2020, representing a $6.6 million increase[112]. - General and administrative expenses rose to $4.1 million in the first half of 2021, compared to $0.6 million in the same period of 2020, marking a $3.5 million increase[113]. Cash and Funding - As of June 30, 2021, the accumulated deficit was $51.3 million, with total gross proceeds from private placements and the IPO amounting to $346.8 million[90]. - The company believes its existing cash and cash equivalents of $299.2 million will fund operations for at least the next 24 months[90]. - The company had cash, cash equivalents, and marketable securities totaling $299.2 million as of June 30, 2021, following gross proceeds of $186.1 million from its IPO[116]. - Net cash provided by financing activities was $186.1 million for the six months ended June 30, 2021, primarily from the IPO, compared to $0.1 million in 2020[121]. - The company expects to require substantial additional capital to fund ongoing operations and product development, particularly as it seeks regulatory approvals and commercializes products[124]. Interest Income - Interest income increased to $107,000 for the three months ended June 30, 2021, compared to $3,000 in 2020, due to higher cash and marketable securities balances[109]. - The increase in interest income to $149,000 in the first half of 2021 from $66,000 in 2020 was due to higher cash and marketable securities balances[114]. Company Classification - The company is classified as an "emerging growth company" and will adopt new accounting standards on the relevant dates for private companies[140]. - The company will remain an emerging growth company until it exceeds $1.07 billion in annual revenue or meets other specified criteria[142]. - The company is also a "smaller reporting company" with a market value of stock held by non-affiliates below $700 million and annual revenue under $100 million[143]. Risk Factors - The company had no outstanding debt as of June 30, 2021, thus no exposure to interest rate risk related to debt[145]. - The company is subject to foreign currency exchange risk due to service agreements in currencies other than the U.S. Dollar, primarily the British Pound and Euro[146]. - A hypothetical 10% change in foreign exchange rates would not have materially impacted the company's financial condition or results of operations[146]. - There was no material foreign currency risk for the three and six months ended June 30, 2021[147].